RESUMEN
BACKGROUND: Allergen immunotherapy (AIT) has a longstanding history and still remains the only disease-changing treatment for allergic rhinitis and asthma. Over the years 2 different schools have developed their strategies: the United States (US) and the European. Allergen extracts available in these regions are adapted to local practice. In other parts of the world, extracts from both regions and local ones are commercialized, as in Mexico. Here, local experts developed a national AIT guideline (GUIMIT 2019) searching for compromises between both schools. METHODS: Using ADAPTE methodology for transculturizing guidelines and AGREE-II for evaluating guideline quality, GUIMIT selected 3 high-quality Main Reference Guidelines (MRGs): the European Academy of Allergy, Asthma and Immunology (EAACI) guideines, the S2k guideline of various German-speaking medical societies (2014), and the US Practice Parameters on Allergen Immunotherapy 2011. We formulated clinical questions and based responses on the fused evidence available in the MRGs, combined with local possibilities, patient's preference, and costs. We came across several issues on which the MRGs disagreed. These are presented here along with arguments of GUIMIT members to resolve them. GUIMIT (for a complete English version, Supplementary data) concluded the following. RESULTS: Related to the diagnosis of IgE-mediated respiratory allergy, apart from skin prick testing complementary tests (challenges, in vitro testing and molecular such as species-specific allergens) might be useful in selected cases to inform AIT composition. AIT is indicated in allergic rhinitis and suggested in allergic asthma (once controlled) and IgE-mediated atopic dermatitis. Concerning the correct subcutaneous AIT dose for compounding vials according to the US school: dosing tables and formula are given; up to 4 non-related allergens can be mixed, refraining from mixing high with low protease extracts. When using European extracts: the manufacturer's indications should be followed; in multi-allergic patients 2 simultaneous injections can be given (100% consensus); mixing is discouraged. In Mexico only allergoid tablets are available; based on doses used in all sublingual immunotherapy (SLIT) publications referenced in MRGs, GUIMIT suggests a probable effective dose related to subcutaneous immunotherapy (SCIT) might be: 50-200% of the monthly SCIT dose given daily, maximum mixing 4 allergens. Also, a table with practical suggestions on non-evidence-existing issues, developed with a simplified Delphi method, is added. Finally, dissemination and implementation of guidelines is briefly discussed, explaining how we used online tools for this in Mexico. CONCLUSIONS: Countries where European and American AIT extracts are available should adjust AIT according to which school is followed.
RESUMEN
El riesgo cardiovascular es responsable de un cuarto de las muertes por enfermedad coronaria, y dentro de estos pacientes el 75% son mayores de 65 años de edad, población a la que nos enfocaremos en esta revisión. Por ello es de suma importancia considerar tanto los beneficios clínicos como económicos de una terapia preventiva en este grupo poblacional. La prescripción en los ancianos se ha convertido en la actualidad en una cuestión compleja que tiende a incrementar el uso irracional de los fármacos, los errores de medicación, los efectos adversos, así como la subutilización o sobreutilización de los mismos. Las estatinas (inhibidores de la HMG-CoA reductasa), son consideradas como el tratamiento hipolipemiante de primera elección para la disminución del riesgo cardiovascular y a pesar de no haber publicaciones enfocadas en el uso exclusivo de estatinas en la población de adultos mayores así como de múltiples controversias, se pueden encontrar beneficios similares a los percibidos en poblaciones más jóvenes, pero con un enfoque en prevención primaria en la población de edad avanzada.
The cardiovascular risk is responsible for a quarter splits of deaths by coronary illness and inside these patients, three quarter splits are greater than 65 years old. Because of it, it's very important to consider the clinical and economic benefits of a preventive therapy in this population group. The statins (inhibiting of the HMG-CoA reductasa), are considered as the greater hypolipemic therapy election for decrease the cardiovascular risk and in spite of not there to be publications focused in the exclusive use of statins in the population of older adults, besides multiple controversies, similar benefits to them can be found perceived in younger populations, but with a focus in primary prevention in the population of advanced age.